We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urine Test Could Diagnose Sporadic Creutzfeldt-Jakob Disease

By LabMedica International staff writers
Posted on 20 Oct 2016
Prions are infectious agents that cause invariably fatal brain diseases such as Creutzfeldt-Jakob Disease (CJD) in humans, scrapie in sheep and bovine spongiform encephalopathy (BSE or 'mad cow disease') in cattle.

They are a rare but important cause of dementia and it is increasingly recognized that the fundamental process involved in these diseases are prion proteins changing shape and sticking together to form fibers or polymers that damage the brain.

Scientists at the University College London (London, UK) carried out retrospective, cross-sectional study and analyzed anonymized urine samples from 162 people including 91 controls, patients known not to have the disease, 34 patients with non-prion neurodegenerative disease, and 37 patients with prion disease, 20 of whom had a sporadic form of Creutzfeldt-Jakob Disease (sCJD). More...
The main outcome of the study was the presence of sCJD infection determined by an assay that captures, enriches, and detects disease-associated prion protein isoforms.

The assay’s specificity for prion disease was 100%, with no false-positive reactions from 125 control individuals, including 34 from a range of neurodegenerative diseases. In contrast to a previous study, which used a different method, sensitivity to variant CJD (vCJD) infection was low (7.7%) with only 1 of 13 patients with positive test results, while sensitivity to sCJD was unexpectedly high at 40%. The scientists hope to be able to increase the performance of the test by isolating the molecule or molecules in urine that are present in patients with sCJD.

Currently, the only ways to determine in life whether or not a patient has sCJD are complex and may include magnetic resonance imaging (MRI) scans, brain biopsy and sampling of cerebrospinal fluid. These procedures are usually only performed when there is already a high likelihood that a patient has the disease, and sadly, the patient may have just weeks to live by the time the diagnosis is confirmed. The urine test was based on a modification of a previously reported direct detection blood test for the presence of abnormal prion proteins.

Graham S. Jackson, PhD, the lead author of the study, said, “Although there is currently no cure for this disease, an accurate and early diagnosis is extremely important for patients and their families. This test could be a critical step forward in being able to identify disease sufferers early using a simple test, perhaps at the first signs of being unwell or even as part of routine screening. By studying the nature of these disease-specific forms of the prion protein we hope to be able to improve the reliability and speed of the test to a point where it could one day be routinely used by clinicians including GPs to detect all forms of CJD.” The study was published on October 3, 2016, in the journal JAMA Neurology.

Related Links:
University College London


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.